Pathology: mNSCLC - L1 - PDL1 positive;
mNSCLC - L1 - PDL1 positive | ||||
MYSTIC (DT ; PDL1>25%), 2020 | CheckMate 227 (NI vs C ; PDL1>1%), 2018 | KEYNOTE-598, 2020 | ||
durvalumab plus tremelimumab | 1 | T1 | ||
pembrolizumab plus ipilimumab | 1 | T1 | ||
nivolumab plus ipilimumab | 1 | T1 | ||
Standard of Care (SoC) | 0 | T0 | ||
pembrolizumab plus placebo | 0 | T0 | ||
pemetrexed plus platin | 0 | T0 |